Log in

Relevant bibliographies by topics / Targeted Drug Regimens / Journal articles

To see the other types of publications on this topic, follow the link: Targeted Drug Regimens.

Journal articles on the topic 'Targeted Drug Regimens'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Targeted Drug Regimens.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

NIYOZOVA, Shakhnoza, and Sergey KAMISHOV. "TARGETED THERAPY IN THE TREATMENT OF PATIENTS METASTATIC COLORECTAL CANCER." Journal of biomedicine and practice 7, no. 4 (2022): 6. https://doi.org/10.5281/zenodo.7027285.

Full text

Abstract:

Objective: to study the possibilities of targeted therapy in patients with metastatic colorectal cancer (CRC). Methods: three groups of 75 CRC patients with liver metastases received standard chemotherapy regimens (CT) XELOX and FOLFOX4; in the experimental groups, the treatment regimens included targeted drugs bevacizumab and cetuximab. Results: the addition of targeted drugs to the treatment regimens for patients with metastatic CRC significantly increased both the overall survival of patients and increased the time for the appearance of signs of disease progression. The median follow-up was

APA, Harvard, Vancouver, ISO, and other styles

2

Mehta, Sandhya, Jinlin Song, Melissa Pavilack, et al. "Utilization of anti-HER2 regimens among HER2-positive metastatic breast cancer patients." Journal of Clinical Oncology 38, no. 29_suppl (2020): 282. http://dx.doi.org/10.1200/jco.2020.38.29_suppl.282.

Full text

Abstract:

282 Background: HER2-positive (+) metastatic breast cancer (mBC) has a poor prognosis and many patients require multiple lines of HER2 targeted regimens. This study aims to examine the treatment sequencing of anti-HER2 regimens for HER2+ mBC among Medicare beneficiaries. Methods: A retrospective study was conducted using linked 1999-2016 Surveillance, Epidemiology, and End Results (SEER) cancer registries and Medicare claims. Adults patients who had mBC diagnosis, HER2+ status documented in SEER or claims of ≥1 anti-HER2 drug, continuous enrollment in Medicare from the date of mBC diagnosis un

APA, Harvard, Vancouver, ISO, and other styles

3

Levêque, Dominique. "Improving the Dosing Schedules of Targeted Anticancer Agents." Pharmaceuticals 18, no. 6 (2025): 848. https://doi.org/10.3390/ph18060848.

Full text

Abstract:

Beyond developing new agents, cancer treatment can also be optimized by modifying the dosing regimen of approved drugs. Academic teams have experimented with different ways of improving drug regimens, leading to off-label practices for therapeutic and/or economic purposes, and currently, drug regulatory agencies have begun to reappraise this often-neglected topic. This concept also considers the patient’s perspective in terms of quality of life and convenience, including the concept of time toxicity. Overall, the optimization of drug dosing of anticancer agents may be viewed on three sides: th

APA, Harvard, Vancouver, ISO, and other styles

4

Luchinin, E. A., M. V. Zhuravleva, T. V. Shelekhova, V. S. Bogova, and E. V. Luchinina. "Application of the cost-effectiveness method in improving the pharmacotherapy of multiple myeloma." Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice, no. 1 (April 19, 2023): 15–25. http://dx.doi.org/10.37489/2588-0519-2023-1-15-25.

Full text

Abstract:

Multiple myeloma (MM) accounts for 1 % of all cancers and about 10 % of all hemoblastoses. The use of innovative technologies with the inclusion of targeted drugs leads to a significant improvement in the quality of pharmacotherapy and the achievement of overall survival (OS).The aim of the work is to conduct a pharmacoeconomic analysis of the most used MM therapy regimens with the use of targeted drugs and to determine the dominant treatment regimens using a costeffectiveness analysis.Materials and methods. To determine the cost of a course of treatment, we summed up the costs of drugs includ

APA, Harvard, Vancouver, ISO, and other styles

5

Ayupov, R. T., A. A. Izmailov, K. V. Menshikov, et al. "Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCURency." Meditsinskiy sovet = Medical Council, no. 20 (December 9, 2021): 47–52. http://dx.doi.org/10.21518/2079-701x-2021-20-47-52.

Full text

Abstract:

Colon cancer therapy currently includes at least 3 cytostatic agents and 6 targeted drugs, combinations of which constitute many different treatment regimens. Nevertheless, as shown by various clinical studies, the use of oxaliplatin, irinotecan and fluoropyrimidine regimens in conjunction with monoclonal targeted drugs remains the main one. After progression on the main lines of therapy and registration of refractory disease, there are not many standard options for treatment in the 3rd line that have statistical confidence in terms of improving survival rates. There have been attempts to sear

APA, Harvard, Vancouver, ISO, and other styles

6

Chaudhuri, Aiswarya, Dulla Naveen Kumar, Deepa Dehari, et al. "Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)." Pharmaceuticals 15, no. 5 (2022): 542. http://dx.doi.org/10.3390/ph15050542.

Full text

Abstract:

Triple-negative breast cancer (TNBC) is considered one of the un-manageable types of breast cancer, involving devoid of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER 2) receptors. Due to their ability of recurrence and metastasis, the management of TNBC remains a mainstay challenge, despite the advancements in cancer therapies. Conventional chemotherapy remains the only treatment regimen against TNBC and suffers several limitations such as low bioavailability, systemic toxicity, less targetability, and multi-drug resistance. Although various targeted therapies have

APA, Harvard, Vancouver, ISO, and other styles

7

Bolotina, L. V., and A. D. Kaprin. "Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices." Medical Council, no. 19 (November 11, 2018): 22–26. http://dx.doi.org/10.21518/2079-701x-2018-19-22-26.

Full text

Abstract:

The most effective first-and subsequent line drug regimens for metastatic colorectal cancer (mCRC) suggest the inclusion of targeted drugs (TD). The choice of TD for the second-line therapy takes into account not only the biological features of the tumor and the general condition of the patient, but also the option of the previous line therapy, its effectiveness and toxicity. Treatment with anti-EGFR antibodies (AT) did not significant improve overall survival (OS) in comparison with chemotherapy in the secondline regimens, in contrast to antiangiogenic drugs. Among this group of MAT, afliberc

APA, Harvard, Vancouver, ISO, and other styles

8

Liu, Xiyan. "Research on the Treatment of Neuro - Oncological Tumors with Targeted Drugs." Theoretical and Natural Science 113, no. 1 (2025): 49–54. https://doi.org/10.54254/2753-8818/2025.au24098.

Full text

Abstract:

Gliomas have a relatively high incidence and a remarkable degree of malignancy. Traditional treatment methods often have adverse effects on the central nervous system during their application. Targeted drugs, as a cutting - edge treatment approach, can precisely act on specific targets of tumor cells and imped the growth, proliferation, survival, and metastasis processes of tumor cells. This article elaborates on the classification of neuro - oncological tumors and targeted drugs and deeply analyzes the mechanism of targeted drugs in the treatment of neuro - oncological tumors from aspects suc

APA, Harvard, Vancouver, ISO, and other styles

9

Kendall, Emily A., Shelly Malhotra, Sarah Cook-Scalise, David W. Dowdy, and Claudia M. Denkinger. "Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model." Clinical Infectious Diseases 71, no. 11 (2019): 2889–96. http://dx.doi.org/10.1093/cid/ciz1179.

Full text

Abstract:

Abstract Background To appropriately treat tuberculosis (TB) with regimens that combine novel and older drugs, evidence-based, context-specific strategies for drug-susceptibility testing (DST) will be required. Methods We created a Markov state-transition model of 100 000 adults with TB receiving a novel, fluoroquinolone (FQ)–containing regimen. We estimated clinical outcomes and resource utilization with no FQ-DST, universal FQ-DST, or FQ-DST only for patients with rifampin-resistant TB (“targeted FQ-DST”). We considered scenarios of stronger (South Africa) and weaker (Southeast Asia) correla

APA, Harvard, Vancouver, ISO, and other styles

10

Qu, Hongchen, Zhongyi Mu, Kai Wang, and Bin Hu. "A Network Meta-Analysis of the Differences in Effectiveness and Safety between Nivolumab and Targeted Drug Therapy in Metastatic Renal Cell Carcinoma." Journal of Oncology 2022 (March 28, 2022): 1–8. http://dx.doi.org/10.1155/2022/5805289.

Full text

Abstract:

Objective. Nivolumab plus other drugs have provided significant benefits in patients with metastatic renal cell carcinoma (mRCC), but most of the available comparisons were conducted with sunitinib, and differences in efficacy with targeted drugs were marginally reported. Thus, this study used a network meta-analysis to compare the difference in efficacy between nivolumab combination therapy and other targeted agents. Methods. In this systematic review and network meta-analysis, we searched PubMed, Embase, and Cochrane Library databases for randomized controlled trials (RCTs) with the time set

APA, Harvard, Vancouver, ISO, and other styles

11

Shankaraiah, Nagula, Shalini Nekkanti, Ojaswitha Ommi, and Lakshmi Soukya P.S. "Diverse Targeted Approaches to Battle Multidrug Resistance in Cancer." Current Medicinal Chemistry 26, no. 39 (2019): 7059–80. http://dx.doi.org/10.2174/0929867325666180410110729.

Full text

Abstract:

: The efficacy of successful cancer therapies is frequently hindered by the development of drug resistance in the tumor. The term ‘drug resistance’ is used to illustrate the decreased effectiveness of a drug in curing a disease or alleviating the symptoms of the patient. This phenomenon helps tumors to survive the damage caused by a specific drug or group of drugs. In this context, studying the mechanisms of drug resistance and applying this information to design customized treatment regimens can improve therapeutic efficacy as well as the curative outcome. Over the years, numerous Multidrug R

APA, Harvard, Vancouver, ISO, and other styles

12

Darenskaya, A. D., N. V. Dobrova, and B. M. Medvedeva. "Cetuximab in treatment of metastatic colorectal cancer: background and clinical observation." Medical Council, no. 19 (November 11, 2018): 32–41. http://dx.doi.org/10.21518/2079-701x-2018-19-32-41.

Full text

Abstract:

Today, the researchers continue the search for the most optimal regimens of drug therapy for metastatic colorectal cancer (mCRC) which are supposed to increase progression-free survival (PFS) and overall survival (OS), improve patient quality of life. Due to significant progress in chemotherapy (CT) and surgical treatment of mCRC, and the multidisciplinary approach, the treatment algorithms have changed. The increase in life expectancy of patients is observed when all three of the most active chemotherapy drugs in this disease: oxaliplatin (Oxa), irinotecan (Iri), fluoropyrimidines are adminis

APA, Harvard, Vancouver, ISO, and other styles

13

Cao, Yi, Yunjin Li, Ruijie Liu, Jianhua Zhou, and Kuansong Wang. "Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer." Cancers 15, no. 9 (2023): 2568. http://dx.doi.org/10.3390/cancers15092568.

Full text

Abstract:

The amplification of epidermal growth factor receptor 2 (HER2) is associated with a poor prognosis and HER2 gene is overexpressed in approximately 15–30% of breast cancers. In HER2-positive breast cancer patients, HER2-targeted therapies improved clinical outcomes and survival rates. However, drug resistance to anti-HER2 drugs is almost unavoidable, leaving some patients with an unmet need for better prognoses. Therefore, exploring strategies to delay or revert drug resistance is urgent. In recent years, new targets and regimens have emerged continuously. This review discusses the fundamental

APA, Harvard, Vancouver, ISO, and other styles

14

Keil, Marlen, Theresia Conrad, Michael Becker, et al. "Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data." Cancers 13, no. 23 (2021): 6018. http://dx.doi.org/10.3390/cancers13236018.

Full text

Abstract:

The current standard therapies for advanced, recurrent or metastatic colon cancer are the 5-fluorouracil and oxaliplatin or irinotecan schedules (FOxFI) +/− targeted drugs cetuximab or bevacizumab. Treatment with the FOxFI cytotoxic chemotherapy regimens causes significant toxicity and might induce secondary cancers. The overall low efficacy of the targeted drugs seen in colon cancer patients still is hindering the substitution of the chemotherapy. The ONCOTRACK project developed a strategy to identify predictive biomarkers based on a systems biology approach, using omics technologies to ident

APA, Harvard, Vancouver, ISO, and other styles

15

Pepe, Felice, and Veronica Balatti. "Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia." Journal of Clinical Medicine 9, no. 2 (2020): 593. http://dx.doi.org/10.3390/jcm9020593.

Full text

Abstract:

In the past decade, novel targeted therapy approaches, such as BTK inhibitors and Bcl2 blockers, and innovative treatments that regulate the immune response against cancer cells, such as monoclonal antibodies, CAR-T cell therapy, and immunomodulatory molecules, have been established to provide support for the treatment of patients. However, drug resistance development and relapse are still major challenges in CLL treatment. Several studies revealed that non-coding RNAs have a main role in the development and progression of CLL. Specifically, microRNAs (miRs) and tRNA-derived small-RNAs (tsRNAs

APA, Harvard, Vancouver, ISO, and other styles

16

Huber, Matthew, and Brian Huber. "Innovation in Oncology Drug Development." Journal of Oncology 2019 (November 23, 2019): 1–16. http://dx.doi.org/10.1155/2019/9683016.

Full text

Abstract:

Significant progress has been made in our understanding of the molecular lesions responsible for tumor cells to exhibit uncontrolled growth while circumventing normal mechanisms of apoptosis and their ability to migrate and invade normal tissues while evading recognition and destruction by the immune system. This understanding has enabled the development of therapies specifically targeted to these lesions coupled to innovative treatment regimens to most effectively use these new targeted therapies with precision in selected subpopulations of patients. Innovation at the scientific and clinical

APA, Harvard, Vancouver, ISO, and other styles

17

Kenny, Reece G., and Celine J. Marmion. "Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?" Chemical Reviews 119, no. 2 (2019): 1058–137. http://dx.doi.org/10.1021/acs.chemrev.8b00271.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Ding, Shengli, Preeti Kanikarla Marie, Nicholas Baro, et al. "Refractory colorectal cancer patient derived MicroOrganoSpheres (MOS) to enable correlation of targeted therapy combination response with clinical outcomes." Journal of Clinical Oncology 41, no. 16_suppl (2023): e15574-e15574. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e15574.

Full text

Abstract:

e15574 Background: Metastatic colorectal cancer (CRC) patients who have become resistant to standard-of-care (SOC) treatments are often put on targeted therapies, including experimental drugs still in clinical trials. However, patients with targeted mutations still often do not respond to the targeted therapies alone, hence it remains a critically unmet need to explore potential combinatorial regimens that will enhance the efficacy. Methods: We performed a high-throughput screen using MicroOrganoSpheres (MOS) derived from metastatic refractory patients to correlate with clinical outcomes and e

APA, Harvard, Vancouver, ISO, and other styles

19

Buya, Aristote B., Bwalya A. Witika, Alain M. Bapolisi, et al. "Application of Lipid-Based Nanocarriers for Antitubercular Drug Delivery: A Review." Pharmaceutics 13, no. 12 (2021): 2041. http://dx.doi.org/10.3390/pharmaceutics13122041.

Full text

Abstract:

The antimicrobial drugs currently used for the management of tuberculosis (TB) exhibit poor bioavailability that necessitates prolonged treatment regimens and high dosing frequency to achieve optimal therapeutic outcomes. In addition, these agents cause severe adverse effects, as well as having detrimental interactions with other drugs used in the treatment of comorbid conditions such as HIV/AIDS. The challenges associated with the current TB regimens contribute to low levels of patient adherence and, consequently, the development of multidrug-resistant TB strains. This has led to the urgent n

APA, Harvard, Vancouver, ISO, and other styles

20

Pyadushkina, E. A., E. V. Derkach, V. I. Ignatyeva, et al. "Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting." FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology 14, no. 2 (2021): 136–50. http://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2021.098.

Full text

Abstract:

Background. The introduction of innovative drugs has significantly increased the treatment effectiveness in patients with relapsed/refractory multiple myeloma (RRMM), but the question of whether these expensive options can be financially secured remains open.Objective: to assess the cost of triplets of targeted drugs ixazomib, carfilzomib, elotuzumab and daratumumab with lenalidomide and dexamethasone used in the treatment of RRMM, and to determine possible payment options for this therapy at the level of the Russian Federation subjects.Material and methods. The cost of an annual course of tre

APA, Harvard, Vancouver, ISO, and other styles

21

Serna, Naroa, Aïda Falgàs, Annabel García-León, et al. "Time-Prolonged Release of Tumor-Targeted Protein–MMAE Nanoconjugates from Implantable Hybrid Materials." Pharmaceutics 14, no. 1 (2022): 192. http://dx.doi.org/10.3390/pharmaceutics14010192.

Full text

Abstract:

The sustained release of small, tumor-targeted cytotoxic drugs is an unmet need in cancer therapies, which usually rely on punctual administration regimens of non-targeted drugs. Here, we have developed a novel concept of protein–drug nanoconjugates, which are packaged as slow-releasing chemically hybrid depots and sustain a prolonged secretion of the therapeutic agent. For this, we covalently attached hydrophobic molecules (including the antitumoral drug Monomethyl Auristatin E) to a protein targeting a tumoral cell surface marker abundant in several human neoplasias, namely the cytokine rece

APA, Harvard, Vancouver, ISO, and other styles

22

Pak, M. B., P. A. Zeynalova, A. M. Mudunov, S. V. Berelavichus, F. U. Tankieva, and I. A. Duguzheva. "Adequate antiemetic treatment in patients receiving antitumor drug therapy." Head and Neck Tumors (HNT) 14, no. 2 (2024): 27–35. http://dx.doi.org/10.17650/2222-1468-2024-14-2-27-35.

Full text

Abstract:

Despite the widespread use of immuno-oncological and targeted therapy in the treatment of malignant tumors, in real clinical practice the role of chemotherapy is still significant, used both in mono regimen and in combination with other antitumor drugs. Cytostatics cause a wide range of adverse events, which are often the cause of dose reduction, cyclical disorders, or even discontinuation of therapy. One of the most common symptoms is chemotherapy-induced nausea and vomiting which affect not only the quality of life, but also the results of treatment. It is important to address these issues f

APA, Harvard, Vancouver, ISO, and other styles

23

McCafferty, Jonathan, Kartikey Grover, Li Li, et al. "A systematic analysis of off-label drug use in real-world data (RWD) across more than 145,000 cancer patients." Journal of Clinical Oncology 37, no. 15_suppl (2019): e18031-e18031. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18031.

Full text

Abstract:

e18031 Background: Off-label drug use is common in cancer treatment (tx) due to limited approved tx options. Systematic analysis of RWD for off-label drug use facilitates hypothesis generation and design of clinical studies for new indications. Methods: We analyzed systemic tx data of > 145,000 cancer patients at Mount Sinai hospitals for 60 chemotherapy, 80 targeted, 16 hormonal therapy drugs, and 6 immune checkpoint inhibitors (CPIs). Off-label use was determined when patients received a drug for cancer indications that had not received regulatory approval, and the tx was not in a clinica

APA, Harvard, Vancouver, ISO, and other styles

24

Guo, Yaqiong, Pengwei Deng, Wenwen Chen, and Zhongyu Li. "Modeling Pharmacokinetic Profiles for Assessment of Anti-Cancer Drug on a Microfluidic System." Micromachines 11, no. 6 (2020): 551. http://dx.doi.org/10.3390/mi11060551.

Full text

Abstract:

The pharmacokinetic (PK) properties of drug, which include drug absorption and excretion, play an important role in determining the in vivo pharmaceutical activity. However, current in vitro systems that model PK profiles are often limited by the in vivo-like concentration profile of a drug. Herein, we present a perfused and multi-layered microfluidic chip system to model the PK profile of anti-cancer drug 5-FU in vitro. The chip device contains two layers of culture channels sandwiched by a porous membrane, which allows for drug exposure and diffusion between the two channels. The integration

APA, Harvard, Vancouver, ISO, and other styles

25

Ding, Shengli, Preeti Kanikarla Marie, Ray Zhang, et al. "Identifying targeted therapy combination for refractory colorectal cancer using micro-organospheres." Journal of Clinical Oncology 41, no. 4_suppl (2023): 27. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.27.

Full text

Abstract:

27 Background: Metastatic colorectal cancer (CRC) patients who have become resistant to standard-of-care (SOC) treatments are often put on targeted therapies. However, patients with targeted mutations still often do not respond to the targeted therapies alone, hence it remains a critically unmet need to explore potential combinatorial regimens that will enhance the efficacy. Using micro-organospheres (MOS) derived from metastatic refractory patients who received targeted therapies, we performed a high-throughput combo screen and compared the response of these patient tumor avatars with their c

APA, Harvard, Vancouver, ISO, and other styles

26

Ku, Jennifer, Emily Henkle, Kathleen F. Carlson, et al. "192. Tolerability Outcomes of Multi-drug Antibiotic Treatment for Pulmonary Nontuberculous Mycobacterial Disease due to Mycobacterium avium Complex in U.S. Medicare Beneficiaries with Bronchiectasis." Open Forum Infectious Diseases 8, Supplement_1 (2021): S116—S117. http://dx.doi.org/10.1093/ofid/ofab466.192.

Full text

Abstract:

Abstract Background Nontuberculous mycobacteria (NTM), most frequently Mycobacterium avium complex (MAC), cause increasingly common pulmonary infections. Treatment interruptions and early discontinuation are common in MAC therapy, but population-based data on treatment outcomes are severely lacking. We examined tolerability outcomes of guideline-based 3-drug therapies (GBT) targeted for pulmonary MAC infection. Methods Among beneficiaries with bronchiectasis (ICD-9-CM 494.0 or 494.1) in U.S. Medicare data (01/2006 – 12/2014), we identified first-time MAC GBT therapy users, excluding those with

APA, Harvard, Vancouver, ISO, and other styles

27

Jitaree, Kamonchanok, Korbtham Sathirakul, Jantana Houngsaitong, et al. "Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Escherichia coli." Antibiotics 8, no. 3 (2019): 125. http://dx.doi.org/10.3390/antibiotics8030125.

Full text

Abstract:

The purpose was to explore the optimal dosage regimen of colistin using Monte Carlo simulations, for the treatment of carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Escherichia coli based on PK/PD targets in critically ill patients. A total of 116 carbapenem-resistant K. pneumoniae and E. coli were obtained from various clinical specimens at Siriraj Hospital in Bangkok, Thailand. Minimum inhibitory concentrations (MICs) of colistin were determined by broth microdilution method. Monte Carlo simulation was used to calculate the cumulative fraction of response (CFR) for Europ

APA, Harvard, Vancouver, ISO, and other styles

28

Rastogi, Sameer, Aditi Aggarwal, Akash Tiwari, and Vinod Sharma. "Chemotherapy in Nonmetastatic Osteosarcoma: Recent Advances and Implications for Developing Countries." Journal of Global Oncology, no. 4 (December 2018): 1–5. http://dx.doi.org/10.1200/jgo.2016.007336.

Full text

Abstract:

Purpose Osteosarcoma (OS) is a relatively chemosensitive primary bone tumor, with the peak age of onset occurring in late childhood and early adolescence. The treatment paradigm of nonmetastatic OS has typically been multimodality therapy, including neoadjuvant and adjuvant chemotherapy with definitive surgery. Over the years, various permutations and combinations of chemotherapeutic agents have been used. However, the majority of recent trials have still used high-dose methotrexate as the backbone, with cisplatin and doxorubicin (MAP). In the last decade, various strategies targeted to improv

APA, Harvard, Vancouver, ISO, and other styles

29

Look, Michael W., Eric Stern, Qin Wang, Leah DiPlacido, Joseph E. Craft, and Tarek M. Fahmy. "Lupus immunotherapy using CD4 targeted nanoparticles (48.29)." Journal of Immunology 182, no. 1_Supplement (2009): 48.29. http://dx.doi.org/10.4049/jimmunol.182.supp.48.29.

Full text

Abstract:

Abstract The pathogenesis of systemic lupus erythematosus is mediated by collaborations between CD4 T cells and B cells with autoantibody production. We propose that the use of biodegradable, nanoparticulate materials that are targeted against CD4 T cells and carry immunosuppressive drugs and proteins can be used to treat lupus. Biodegradable nanoparticles exhibit excellent therapeutic features such as biocompatibility, targeting potential, and controlled release rates of its encapsulated cargo. Here, we report results demonstrating the therapeutic efficacy of using nanoparticles to suppress l

APA, Harvard, Vancouver, ISO, and other styles

30

Văruț, Renata Maria, Alin Iulian Silviu Popescu, Simina Gaman, et al. "Cyclodextrin-Based Drug Delivery Systems for Depression: Improving Antidepressant Bioavailability and Targeted Central Nervous System Delivery." Pharmaceutics 17, no. 3 (2025): 355. https://doi.org/10.3390/pharmaceutics17030355.

Full text

Abstract:

Cyclodextrin (CD)-based drug delivery systems have emerged as a promising strategy to overcome limitations commonly encountered in antidepressant therapy, including low bioavailability, poor solubility, and suboptimal penetration of the blood–brain barrier. This review synthesizes current evidence demonstrating that complexing various classes of antidepressants—such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and atypical antidepressants—with β-CD or its derivatives significantly enhances drug solubility and stability. In addition, encapsulation with C

APA, Harvard, Vancouver, ISO, and other styles

31

Ang, Michelle Lay Teng, Si Min Chan, Lionel Tim-Ee Cheng, et al. "Singapore tuberculosis (TB) clinical management guidelines 2024: A modified Delphi adaptation of international guidelines for drug-susceptible TB infection and pulmonary disease." Annals of the Academy of Medicine, Singapore 53, no. 3 - Correct DOI (2024): 170–86. http://dx.doi.org/10.47102/annals-acadmedsg.2023391.

Full text

Abstract:

Introduction: Tuberculosis (TB) remains endemic in Singapore. Singapore’s clinical practice guidelines for the management of tuberculosis were first published in 2016. Since then, there have been major new advances in the clinical management of TB, ranging from diagnostics to new drugs and treatment regimens. The National TB Programme convened a multidisciplinary panel to update guidelines for the clinical management of drug-susceptible TB infection and disease in Singapore, contextualising current evidence for local practice. Method: Following the ADAPTE framework, the panel systematically re

APA, Harvard, Vancouver, ISO, and other styles

32

Ang, Michelle Lay Teng, Si Min Chan, Lionel Tim-Ee Cheng, et al. "Singapore tuberculosis (TB) clinical management guidelines 2024: A modified Delphi adaptation of international guidelines for drug-susceptible TB infection and pulmonary disease." Annals of the Academy of Medicine, Singapore 53, no. 3 (2024): 170–86. http://dx.doi.org/10.47102/https://doi.org/10.47102/annals-acadmedsg.2023391.

Full text

Abstract:

Introduction: Tuberculosis (TB) remains endemic in Singapore. Singapore’s clinical practice guidelines for the management of tuberculosis were first published in 2016. Since then, there have been major new advances in the clinical management of TB, ranging from diagnostics to new drugs and treatment regimens. The National TB Programme convened a multidisciplinary panel to update guidelines for the clinical management of drug-susceptible TB infection and disease in Singapore, contextualising current evidence for local practice. Method: Following the ADAPTE framework, the panel systematically re

APA, Harvard, Vancouver, ISO, and other styles

33

V., N. V. L. Suvarchala Reddy, M. Ganga Raju, Keerthana Edunoori, and Jyothi Papani. "Nano Emulsion: The Targeted Drug Delivery in the Therapy of Epilepsy." International Research Journal of Pure and Applied Chemistry 24, no. 5 (2023): 46–53. http://dx.doi.org/10.9734/irjpac/2023/v24i5824.

Full text

Abstract:

Around the world, 50 million people suffer with epilepsy; it significantly burdens society in terms of finances, society, and health. Our comprehension of the pathophysiological processes causing the illness and the factors affecting its prognosis has significantly advanced during the last ten years. Around a third of patients are still resistive to medical intervention, despite the fact that the number of antiepileptic drugs has expanded dramatically over the past 20 years. The ability of nanotech-based anti-epileptic drug (AED) administration methods to cross the blood brain barrier, increas

APA, Harvard, Vancouver, ISO, and other styles

34

Lee, John J., Alexander Llanos, and Richard Channick. "Whatever Happened to Oral Monotherapy?" Advances in Pulmonary Hypertension 15, no. 4 (2017): 190–92. http://dx.doi.org/10.21693/1933-088x-15.4.190.

Full text

Abstract:

Over the past 20 years, pulmonary arterial hypertension management has evolved dramatically, with development and approval of more than a dozen drugs targeted at 3 cellular pathways. Recent trials, including patients either already on background therapy or up-front combination regimens have shown benefits of combination therapy. However, some patients in these recent trials and in practice seem to benefit from a single drug approach. The role of monotherapy in PAH is reviewed in this paper.

APA, Harvard, Vancouver, ISO, and other styles

35

Wang, Jianzheng, Jinxi Huang, Hui Wang, et al. "Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model." Journal of Oncology 2022 (January 27, 2022): 1–11. http://dx.doi.org/10.1155/2022/1987705.

Full text

Abstract:

Background. The morbidity and mortality of gastric cancer are high in China. There are challenges to develop precise and individualized drug regimens for patients with gastric cancer after a standard treatment. Choosing the most appropriate anticancer drug after a patient developing drug resistance is very important to improve the patient’s prognosis. MiniPDX has been widely used as a new and reliable preclinical research model to predict the sensitivity of anticancer drugs. Methods. The OncoVee® MiniPDX system developed by Shanghai LIDE Biotech Co., Ltd. was used to establish the MiniPDX mode

APA, Harvard, Vancouver, ISO, and other styles

36

Dąbrowska, Anna, Magdalena Grubba, Amar Balihodzic, Olga Szot, Bartosz Kamil Sobocki, and Adrian Perdyan. "The Role of Regulatory T Cells in Cancer Treatment Resistance." International Journal of Molecular Sciences 24, no. 18 (2023): 14114. http://dx.doi.org/10.3390/ijms241814114.

Full text

Abstract:

Despite tremendous progress in cancer treatment in recent years, treatment resistance is still a major challenge for a great number of patients. One of the main causes is regulatory T lymphocytes (Tregs), which suppress excessive inflammatory responses via the secretion of immunosuppressive cytokines and upregulate the immune checkpoints. Their abundance causes an immunosuppressive reprogramming of the tumor environment, which is ideal for tumor growth and drug inefficiency. Hence, regiments that can regain tumor immunogenicity are a promising strategy to overcome Tregs-mediated drug resistanc

APA, Harvard, Vancouver, ISO, and other styles

37

Pereira Gomes, Isabela, Jaqueline Aparecida Duarte, Ana Luiza Chaves Maia, et al. "Thermosensitive Nanosystems Associated with Hyperthermia for Cancer Treatment." Pharmaceuticals 12, no. 4 (2019): 171. http://dx.doi.org/10.3390/ph12040171.

Full text

Abstract:

Conventional chemotherapy regimens have limitations due to serious adverse effects. Targeted drug delivery systems to reduce systemic toxicity are a powerful drug development platform. Encapsulation of antitumor drug(s) in thermosensitive nanocarriers is an emerging approach with a promise to improve uptake and increase therapeutic efficacy, as they can be activated by hyperthermia selectively at the tumor site. In this review, we focus on thermosensitive nanosystems associated with hyperthermia for the treatment of cancer, in preclinical and clinical use.

APA, Harvard, Vancouver, ISO, and other styles

38

Ravi, Durgadevi, Vishwanath kaliyaperumal, Bhuvaneswari Gunasekar, and Shyamaladevi Babu. "Nano-Warriors against Drug-Resistant Tuberculosis: Unleashing Nanoparticles for Enhanced Treatment." Journal of Advanced Zoology 44, S-5 (2023): 2048–52. http://dx.doi.org/10.17762/jaz.v44is-5.1661.

Full text

Abstract:

Tuberculosis (TB) is a global health crisis, with millions of cases and deaths annually. Drug-resistant strains like multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB further complicate treatment. Conventional TB treatment, reliant on lengthy drug regimens, faces issues of non-compliance, drug resistance, and side effects. Nanoparticles (NPs) offer a promising solution. NPs, with their small size and unique properties, can enhance TB drug delivery. They improve drug solubility and stability, minimize side effects, and enable targeted therapy. NPs encapsulate drugs, shielding th

APA, Harvard, Vancouver, ISO, and other styles

39

Grivtsova, L. Yu, O. B. Karyakin, M. G. Syadrin, S. M. Samborsky, S. A. Ivanov, and A. D. Kaprin. "Biomarkers determining treatment tactics in metastatic urothelial cancer." Cancer Urology 19, no. 2 (2023): 111–26. http://dx.doi.org/10.17650/1726-9776-2023-19-2-111-126.

Full text

Abstract:

The implementation of innovative methods of drug therapy and biotherapy into clinical practice has significantly changed the treatment tactics for metastatic urothelial cancer. Currently, treatment regimens are successfully supplemented with immunotherapy (immune checkpoint inhibitors) or targeted therapy, and the effectiveness of such combinations can be quite high, but the optimal sequence of different types of drug therapy remains to be established. The development of correct algorithms using reliable biomarkers is necessary to select the correct sequence of prescribing drugs. Until now, th

APA, Harvard, Vancouver, ISO, and other styles

40

Buchineni, Madhavulu, Jeevimani V. S. Reddy, M. Saritha, et al. "Evaluation of antihypertensive drugs use in a tertiary hospital setting – A cross-sectional study." Journal of Dr. YSR University of Health Sciences 13, no. 3 (2024): 226–30. http://dx.doi.org/10.4103/jdrysruhs.jdrysruhs_18_24.

Full text

Abstract:

ABSTRACT Background: Hypertension, a well-known risk factor for cardiovascular diseases, significantly impacts life expectancy. Managing antihypertensive medications effectively is critical in this context. Aim: To analyze prescription patterns of antihypertensive drugs. Method: This cross-sectional study, spanning six months within the Department of General Medicine, investigated physicians’ prescribed treatment regimens. Results: Most patients fall within the 51–60 age group (35.56%). Notably, males represent the majority demographic (68.15%). Among comorbidities, diabetes mellitus emerged a

APA, Harvard, Vancouver, ISO, and other styles

41

Shaikh, Shoheb S., and Sachin M. Kokate. "Chrono-pharmaceutical approaches to optimize dosing regimens based on the circadian clock machinery." Indian Journal of Pharmacy and Pharmacology 8, no. 4 (2022): 238–42. http://dx.doi.org/10.18231/j.ijpp.2021.042.

Full text

Abstract:

Daily rhythmic variations in biological functions affect the efficacy and/or toxicity of drugs: a large number of drugs cannot be expected to exhibit the same potency at different administration times. The “circadian clock” is an endogenous timing system that broadly regulates metabolism, physiology and behavior. In mammals, this clock governs the oscillatory expression of the majority of genes with a period length of approximately 24 h. Genetic studies have revealed that molecular components of the circadian clock regulate the expression of genes responsible for the sensitivity to drugs and t

APA, Harvard, Vancouver, ISO, and other styles

42

Salaam, Amanee D., Patrick Hwang, Roberus McIntosh, Hadiyah N. Green, Ho-Wook Jun, and Derrick Dean. "Nanodiamond-DGEA peptide conjugates for enhanced delivery of doxorubicin to prostate cancer." Beilstein Journal of Nanotechnology 5 (July 1, 2014): 937–45. http://dx.doi.org/10.3762/bjnano.5.107.

Full text

Abstract:

The field of nanomedicine has emerged as an approach to enhance the specificity and efficacy of cancer treatments as stand-alone therapies and in combination with standard chemotherapeutic treatment regimens. The current standard of care for metastatic cancer, doxorubicin (DOX), is presented with challenges, namely toxicity due to a lack of specificity and targeted delivery. Nano-enabled targeted drug delivery systems can provide an avenue to overcome these issues. Nanodiamonds (ND), in particular, have been researched over the past five years for use in various drug delivery systems but minim

APA, Harvard, Vancouver, ISO, and other styles

43

Bakhtiar, Muhammad, Sepideh Gholami, and Anwaar Saeed. "A systematic review to assess the efficacy of HER2-targeted treatment regimens in HER2-positive metastatic colorectal cancer (mCRC)." Journal of Clinical Oncology 41, no. 4_suppl (2023): 166. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.166.

Full text

Abstract:

166 Background: Recently, there has been a breakthrough in the treatment and disease control of HER-2 positive mCRC using Trastuzumab (TRA) +Tyrosine Kinase inhibitor (TKI) regimens and regimens with trastuzumab based antibody drug conjugates (ADCs). Methods: A total of 14 randomized controlled trials and single arm clinical trials were collected from PubMed, Cochrane library, and Embase. 7 trials were excluded for being duplicate, irrelevant or because of lack of response from the trial researchers. Data from the remaining 7 articles was extracted either from the full publication or from rese

APA, Harvard, Vancouver, ISO, and other styles

44

Wu, Qitong, and Dipali Sharma. "Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy." Cells 12, no. 8 (2023): 1156. http://dx.doi.org/10.3390/cells12081156.

Full text

Abstract:

Despite an increase in the incidence of breast cancer worldwide, overall prognosis has been consistently improving owing to the development of multiple targeted therapies and novel combination regimens including endocrine therapies, aromatase inhibitors, Her2-targeted therapies, and cdk4/6 inhibitors. Immunotherapy is also being actively examined for some breast cancer subtypes. This overall positive outlook is marred by the development of resistance or reduced efficacy of the drug combinations, but the underlying mechanisms are somewhat unclear. It is interesting to note that cancer cells qui

APA, Harvard, Vancouver, ISO, and other styles

45

Zimmerman, Brittney S., and Francisco J. Esteva. "Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer." Cancers 16, no. 4 (2024): 800. http://dx.doi.org/10.3390/cancers16040800.

Full text

Abstract:

Human epidermal growth factor receptor 2 (HER2) tyrosine kinase is overexpressed in 20% of breast cancers and associated with a less favorable prognosis compared to HER2-negative disease. Patients have traditionally been treated with a combination of chemotherapy and HER2-targeted monoclonal antibodies such as trastuzumab and pertuzumab. The HER2-targeted antibody–drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) represent a novel class of therapeutics in breast cancer. These drugs augment monoclonal antibodies with a cytotoxic payload, which is attached b

APA, Harvard, Vancouver, ISO, and other styles

46

Rao, Sarika N., and Maria E. Cabanillas. "Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond." Journal of the Endocrine Society 2, no. 10 (2018): 1109–30. http://dx.doi.org/10.1210/js.2018-00180.

Full text

Abstract:

Abstract Thyroid cancer, with the exception of anaplastic thyroid cancer, typically has very favorable outcomes with the standard therapy. However, those that persist, recur, or metastasize are associated with a worse prognosis. Targeted therapy with kinase inhibitors has shown promise in advanced cases of thyroid cancer, and currently five drug regimens are approved for use in clinical practice in the treatment of differentiated, medullary, and anaplastic thyroid cancer, with more options in the pipeline. However, one of the greatest dilemmas is when and how to initiate one of these drugs, an

APA, Harvard, Vancouver, ISO, and other styles

47

Ding, Shengli, Preeti Kanikarla Marie, Ray Zhang, et al. "Abstract 183: Evaluating targeted therapy combination for refractory colorectal cancer using MicroOrganoSpheres (MOS)." Cancer Research 83, no. 7_Supplement (2023): 183. http://dx.doi.org/10.1158/1538-7445.am2023-183.

Full text

Abstract:

Abstract Metastatic colorectal cancer (CRC) patients who have become resistant to standard-of-care (SOC) treatments are often put on targeted therapies, including experimental drugs still in clinical trials. However, patients with targeted mutations still often do not respond to the targeted therapies alone, hence it remains a critically unmet need to explore potential combinatorial regimens that will enhance the efficacy. We performed a high-throughput screen using MicroOrganoSpheres (MOS) derived from metastatic refractory patients to correlate with clinical outcomes and explore alternative

APA, Harvard, Vancouver, ISO, and other styles

48

Acanda de la Rocha, Arlet Maria, Maggie Fader, Ebony Coats, et al. "Abstract 4103: Feasibility and efficacy of a functional precision medicine approach in the management of relapsed/refractory childhood cancers." Cancer Research 82, no. 12_Supplement (2022): 4103. http://dx.doi.org/10.1158/1538-7445.am2022-4103.

Full text

Abstract:

Abstract Pediatric cancers are fundamentally different from those in adults, with lower frequency of genetic mutations and fewer options for targeted therapies. The implementation of functional precision medicine (FPM) - the integration of ex vivo drug screening and mutation profiling- can, therefore, provide better treatment options for pediatric tumor patients. In this study, we investigated the feasibility and clinical utility of FPM in the management of pediatric patients with recurrent and/or refractory cancers. We use a functional ex vivo drug screening test (DST) panel encompassed 40 fo

APA, Harvard, Vancouver, ISO, and other styles

49

Lou, Jian-Shu, Ping Yao, and Karl W. K. Tsim. "Cancer Treatment by Using Traditional Chinese Medicine: Probing Active Compounds in Anti-multidrug Resistance During Drug Therapy." Current Medicinal Chemistry 25, no. 38 (2019): 5128–41. http://dx.doi.org/10.2174/0929867324666170920161922.

Full text

Abstract:

The main challenge of cancer treatment is multidrug resistance during chemotherapy. Cancer cell can evade cell death during every round of orthodox chemotherapy drugs, consequently being resistant after several rounds of standard drug treatment. One of the regimens to address this multidrug resistance problem is by drug combination. However, synthetic drugs always have problems of strong side effects and toxicity. Natural compounds deriving from traditional Chinese medicine are known to have low toxicity and genuine promising effects in reversing multidrug resistance, either induced by orthodo

APA, Harvard, Vancouver, ISO, and other styles

50

Casadei, Chiara, Nazli Dizman, Giuseppe Schepisi, et al. "Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors." Therapeutic Advances in Medical Oncology 11 (January 2019): 175883591989028. http://dx.doi.org/10.1177/1758835919890285.

Full text

Abstract:

Inhibitors of fibroblast growth factor receptor (FGFR) represent an outstanding treatment approach for selected patients with urothelial cancer (UC). These agents are changing the clinical approach to a subgroup of UC, the luminal-papillary subtype, characterized by FGFR mutations, fusions, or amplification. In this review, we provide an overview of the results of recent clinical trials on FGFR tyrosine kinase inhibitors (TKIs) currently in clinical development for the treatment of UC: erdafitinib, rogaratinib, infigratinib, and the monoclonal antibody vofatamab. The Food and Drug Administrati

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!